Black Diamond Therapeutics (BDTX) News Today $2.05 +0.04 (+1.99%) Closing price 05/27/2025 04:00 PM EasternExtended Trading$2.08 +0.03 (+1.22%) As of 05:51 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock BDTX Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Given Average Rating of "Buy" by AnalystsMay 27 at 3:49 AM | americanbankingnews.comBlack Diamond Therapeutics (NASDAQ:BDTX) Upgraded at Wall Street ZenMay 25 at 2:53 AM | americanbankingnews.comBlack Diamond Therapeutics, Inc. (NASDAQ:BDTX) Receives Average Recommendation of "Buy" from BrokeragesShares of Black Diamond Therapeutics, Inc. (NASDAQ:BDTX - Get Free Report) have earned an average recommendation of "Buy" from the five analysts that are covering the firm, Marketbeat Ratings reports. Five analysts have rated the stock with a buy recommendation. The average 1 year target price amoMay 24, 2025 | marketbeat.comBlack Diamond Therapeutics (NASDAQ:BDTX) Rating Increased to Buy at StockNews.comStockNews.com upgraded Black Diamond Therapeutics from a "hold" rating to a "buy" rating in a research note on Thursday.May 24, 2025 | marketbeat.comBlack Diamond Therapeutics (NASDAQ:BDTX) vs. Taysha Gene Therapies (NASDAQ:TSHA) Head-To-Head ReviewMay 23, 2025 | americanbankingnews.comVestal Point Capital LP Raises Stake in Black Diamond Therapeutics, Inc. (NASDAQ:BDTX)Vestal Point Capital LP boosted its position in Black Diamond Therapeutics, Inc. (NASDAQ:BDTX - Free Report) by 11.4% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 5,600,000 shares of the company's stoMay 21, 2025 | marketbeat.comPrice T Rowe Associates Inc. MD Cuts Position in Black Diamond Therapeutics, Inc. (NASDAQ:BDTX)Price T Rowe Associates Inc. MD reduced its stake in shares of Black Diamond Therapeutics, Inc. (NASDAQ:BDTX - Free Report) by 96.3% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 14,182 shares of the company's stock after selling 365,762May 21, 2025 | marketbeat.comTang Capital Management LLC Purchases 700,000 Shares of Black Diamond Therapeutics, Inc. (NASDAQ:BDTX)Tang Capital Management LLC lifted its stake in shares of Black Diamond Therapeutics, Inc. (NASDAQ:BDTX - Free Report) by 51.1% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,070,209 shares of the company's stoMay 20, 2025 | marketbeat.comDimensional Fund Advisors LP Has $1.42 Million Stake in Black Diamond Therapeutics, Inc. (NASDAQ:BDTX)Dimensional Fund Advisors LP raised its stake in Black Diamond Therapeutics, Inc. (NASDAQ:BDTX - Free Report) by 158.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 661,436 shares of the company's stock after buyingMay 18, 2025 | marketbeat.comWedbush Issues Optimistic Outlook for BDTX EarningsMay 18, 2025 | americanbankingnews.comBlack Diamond Therapeutics, Inc. (NASDAQ:BDTX) Shares Sold by OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLCOCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC trimmed its holdings in Black Diamond Therapeutics, Inc. (NASDAQ:BDTX - Free Report) by 73.2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutionalMay 17, 2025 | marketbeat.comTD Cowen Remains a Buy on Black Diamond Therapeutics (BDTX)May 15, 2025 | theglobeandmail.comBlack Diamond Therapeutics, Inc: Black Diamond Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate UpdateMay 13, 2025 | finanznachrichten.deBlack Diamond Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate UpdateMay 12, 2025 | globenewswire.comPositive week for Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) institutional investors who lost 74% over the past yearMay 4, 2025 | finance.yahoo.comBoxer Capital Management LLC Acquires New Holdings in Black Diamond Therapeutics, Inc. (NASDAQ:BDTX)Boxer Capital Management LLC purchased a new stake in shares of Black Diamond Therapeutics, Inc. (NASDAQ:BDTX - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 506,000 shares of the company's stocMay 4, 2025 | marketbeat.comBlack Diamond Therapeutics (BDTX) to Release Quarterly Earnings on ThursdayBlack Diamond Therapeutics (NASDAQ:BDTX) will be releasing its Q1 2025 earnings before the market opens on Thursday, May 8. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-8-black-diamond-therapeutics-inc-stock/)May 3, 2025 | marketbeat.comT. Rowe Price Investment Management Inc. Sells 267,668 Shares of Black Diamond Therapeutics, Inc. (NASDAQ:BDTX)T. Rowe Price Investment Management Inc. reduced its position in Black Diamond Therapeutics, Inc. (NASDAQ:BDTX - Free Report) by 2.5% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 10,466,721 shares of the company's stock after selling 267,668 sharesApril 29, 2025 | marketbeat.comBlack Diamond Therapeutics, Inc. (NASDAQ:BDTX) Shares Bought by Renaissance Technologies LLCRenaissance Technologies LLC raised its position in shares of Black Diamond Therapeutics, Inc. (NASDAQ:BDTX - Free Report) by 256.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 904,000 shares of the company'sApril 28, 2025 | marketbeat.comBlack Diamond Therapeutics, Inc. (NASDAQ:BDTX) Short Interest Up 42.0% in MarchBlack Diamond Therapeutics, Inc. (NASDAQ:BDTX - Get Free Report) was the target of a large increase in short interest in the month of March. As of March 31st, there was short interest totalling 10,170,000 shares, an increase of 42.0% from the March 15th total of 7,160,000 shares. Based on an average daily volume of 3,290,000 shares, the days-to-cover ratio is presently 3.1 days. Approximately 19.7% of the shares of the company are sold short.April 20, 2025 | marketbeat.comAffinity Asset Advisors LLC Purchases Shares of 559,163 Black Diamond Therapeutics, Inc. (NASDAQ:BDTX)Affinity Asset Advisors LLC acquired a new position in Black Diamond Therapeutics, Inc. (NASDAQ:BDTX - Free Report) during the fourth quarter, according to its most recent filing with the SEC. The firm acquired 559,163 shares of the company's stock, valued at approximately $1,197,000. Affinity AsseApril 17, 2025 | marketbeat.comBlack Diamond Therapeutics, Inc. (NASDAQ:BDTX) Position Reduced by Kennedy Capital Management LLCKennedy Capital Management LLC reduced its position in shares of Black Diamond Therapeutics, Inc. (NASDAQ:BDTX - Free Report) by 34.0% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 433,793 shares of the company's stockApril 17, 2025 | marketbeat.comBlack Diamond Therapeutics to Participate in Upcoming Investor ConferencesMarch 31, 2025 | globenewswire.comBlack Diamond Therapeutics Trades Well Below Cash After Lucrative Deal With ServierMarch 25, 2025 | seekingalpha.comWhat is Wedbush's Estimate for BDTX Q1 Earnings?Black Diamond Therapeutics, Inc. (NASDAQ:BDTX - Free Report) - Equities researchers at Wedbush upped their Q1 2025 earnings estimates for shares of Black Diamond Therapeutics in a research report issued to clients and investors on Wednesday, March 19th. Wedbush analyst R. Driscoll now forecasts tMarch 24, 2025 | marketbeat.comGrowth N. V. Biotech Sells 5,784,292 Shares of Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) StockBlack Diamond Therapeutics, Inc. (NASDAQ:BDTX - Get Free Report) major shareholder Growth N. V. Biotech sold 5,784,292 shares of the firm's stock in a transaction that occurred on Wednesday, March 19th. The shares were sold at an average price of $2.07, for a total transaction of $11,973,484.44. Following the transaction, the insider now directly owns 2,733,547 shares of the company's stock, valued at $5,658,442.29. This represents a 67.91 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Major shareholders that own at least 10% of a company's shares are required to disclose their transactions with the SEC.March 21, 2025 | marketbeat.comStifel Nicolaus Keeps Their Buy Rating on Black Diamond Therapeutics (BDTX)March 21, 2025 | markets.businessinsider.comWhat is HC Wainwright's Estimate for BDTX Q1 Earnings?Black Diamond Therapeutics, Inc. (NASDAQ:BDTX - Free Report) - Equities researchers at HC Wainwright lowered their Q1 2025 EPS estimates for Black Diamond Therapeutics in a report issued on Tuesday, March 18th. HC Wainwright analyst R. Burns now expects that the company will post earnings of ($0.March 21, 2025 | marketbeat.comBlack Diamond Therapeutics, Inc. (NASDAQ:BDTX) Major Shareholder Sells $11,973,484.44 in StockMarch 21, 2025 | insidertrades.comPenny Stocks To Follow Now - March 19thBlack Diamond Therapeutics, Aterian, and Plug Power are the three Penny stocks to watch today, according to MarketBeat's stock screener tool. Penny stocks are low-priced equity shares, usually trading for less than $5 per share, often issued by small, less-established companies. They tend to be higMarch 20, 2025 | marketbeat.comServier and Black Diamond sign deal for solid tumours therapyMarch 20, 2025 | finance.yahoo.comBlack Diamond Therapeutics (NASDAQ:BDTX) Given Outperform Rating at WedbushWedbush reissued an "outperform" rating and issued a $11.00 target price on shares of Black Diamond Therapeutics in a research note on Wednesday.March 20, 2025 | marketbeat.comBlack Diamond Therapeutics Sees Unusually High Options Volume (NASDAQ:BDTX)Black Diamond Therapeutics, Inc. (NASDAQ:BDTX - Get Free Report) was the recipient of unusually large options trading on Wednesday. Stock traders purchased 1,853 call options on the stock. This represents an increase of approximately 1,419% compared to the typical volume of 122 call options.March 20, 2025 | marketbeat.comBlack Diamond, Servier announce global licensing agreement for BDTX-4933March 19, 2025 | markets.businessinsider.comBlack Diamond stock soars on licensing dealMarch 19, 2025 | in.investing.comBlack Diamond Therapeutics Shares Surge on Servier Licensing DealMarch 19, 2025 | marketwatch.comThis Biotech Is Finding Mid-Week Success Following Licensing Agreement AnnouncementMarch 19, 2025 | msn.comBlack Diamond Therapeutics Inks Licensing Pact With French Pharma Firm Servier For Its Early-Stage Cancer Drug Worth Over $700 MillionMarch 19, 2025 | benzinga.comBlack Diamond Therapeutics Shares Jump On New Partnership With France-Based Servier: Retail Sentiment Hits Year-HighMarch 19, 2025 | msn.comBlack Diamond Therapeutics (NASDAQ:BDTX) Price Target Raised to $12.00HC Wainwright increased their price target on shares of Black Diamond Therapeutics from $11.00 to $12.00 and gave the company a "buy" rating in a report on Tuesday.March 19, 2025 | marketbeat.comServier and Black Diamond Therapeutics Announce Global Licensing Agreement for BDTX-4933, A Targeted Oncology TherapyMarch 19, 2025 | tmcnet.comServier and Black Diamond Therapeutics Announce Global Licensing Agreement for BDTX-4933, A Targeted Oncology TherapyMarch 19, 2025 | globenewswire.comBlack Diamond price target raised to $12 from $11 at H.C. WainwrightMarch 18, 2025 | markets.businessinsider.comBlack Diamond Therapeutics: In Decline, But Why?March 13, 2025 | seekingalpha.comAnalysts Are Bullish on These Healthcare Stocks: Mersana Therapeutics (MRSN), Revelation Biosciences (REVB)March 10, 2025 | markets.businessinsider.comBrokers Issue Forecasts for BDTX Q1 EarningsBlack Diamond Therapeutics, Inc. (NASDAQ:BDTX - Free Report) - Investment analysts at Wedbush issued their Q1 2026 EPS estimates for Black Diamond Therapeutics in a research note issued to investors on Friday, March 7th. Wedbush analyst R. Driscoll anticipates that the company will earn ($0.22) pMarch 10, 2025 | marketbeat.comBlack Diamond Therapeutics Q4 Loss Decreases, Beats EstimatesMarch 8, 2025 | nasdaq.comBlack Diamond Therapeutics (NASDAQ:BDTX) Price Target Cut to $15.00 by Analysts at Stifel NicolausStifel Nicolaus dropped their price objective on shares of Black Diamond Therapeutics from $16.00 to $15.00 and set a "buy" rating for the company in a report on Friday.March 8, 2025 | marketbeat.comWedbush Reaffirms Outperform Rating for Black Diamond Therapeutics (NASDAQ:BDTX)Wedbush reaffirmed an "outperform" rating and issued a $11.00 target price (down from $16.00) on shares of Black Diamond Therapeutics in a research note on Friday.March 8, 2025 | marketbeat.comBlack Diamond Therapeutics Reports 2024 Financial ResultsMarch 7, 2025 | tipranks.com Get Black Diamond Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BDTX and its competitors with MarketBeat's FREE daily newsletter. Email Address BDTX Media Mentions By Week BDTX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BDTX News Sentiment▼1.411.03▲Average Medical News Sentiment BDTX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BDTX Articles This Week▼82▲BDTX Articles Average Week Get Black Diamond Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BDTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ORIC News Today MAZE News Today SANA News Today PRTC News Today SIGA News Today ATAI News Today ORKA News Today MGTX News Today AUTL News Today SEPN News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:BDTX) was last updated on 5/28/2025 by MarketBeat.com Staff From Our PartnersTrump Predicts Dollar DownfallREAD THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... ...Augusta Precious Metals | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredF1 Engineering Powers This Electric Marine MotorThe future of marine propulsion has arrived - powered by F-1 grade engineering. In collaboration with McLar...The Tomorrow Investor | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredDo You Believe In President Trump? Answer This 1 QuestionThey said you wouldn’t last—that Bidenflation, Wall Street selloffs, and DEI funds would break your loyalty to...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Black Diamond Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Black Diamond Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy BDTX Stock Free BDTX Stock Alerts